ogkoolrod (@og_Kool_Rod) header
ogkoolrod (@og_Kool_Rod) profile picture
Phoenix, AZ
Joined July 2020
Photo by ogkoolrod (@og_Kool_Rod)Photo by ogkoolrod (@og_Kool_Rod)Photo by ogkoolrod (@og_Kool_Rod)Photo by ogkoolrod (@og_Kool_Rod)Photo by ogkoolrod (@og_Kool_Rod)Photo by ogkoolrod (@og_Kool_Rod)Photo by ogkoolrod (@og_Kool_Rod)Photo by ogkoolrod (@og_Kool_Rod)Photo by ogkoolrod (@og_Kool_Rod)Photo by ogkoolrod (@og_Kool_Rod)
ogkoolrod retweeted
$LQDA at Jefferies - some more color on L606 regulatory pathway. They previously had agreement with FDA on 505b(2) pathway, but per the settlement can no longer reference some needed data for that in PH-ILD. So switched to 505b(1) pathway, which requires two studies - they simply added a PAH study. So adds some complexity and cost but not really much in the way of risk or timeline as studies will read out on similar timelines. Also now no automatic 30-month stay. Re-iterated that existing UTHR patent speaks to "per breath" dosing, which L606 clearly sidesteps.
8
2
56
6,117
ogkoolrod retweeted
$LQDA Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH | Liquidia Corporation liquidia.com/news-releases/n…
4
8
1
39
25,036
ogkoolrod retweeted
valuation: $LQDA — I spent some time reading the cases after the YUTREPIA decision. I’m not a patent lawyer, but I think the market is treating this as far more binary than the law—or economics—actually are. Four cases matter: 1. Ferring v. Watson, 764 F.3d 1382 (Fed. Cir. 2014). Ferring committed during litigation to amend its application to remove the infringing material. Compare Norwich/Salix, where Norwich tried to carve out the patented indication after final judgment and lost. Timing matters. LQDA has already said it intends to submit an NDA supplement removing PH-ILD. If that happens before final judgment, I think the facts look considerably better under Ferring than Norwich. 2. Jazz v. Avadel. Avadel lost the patent case, yet the Delaware court refused to remove already-approved LUMRYZ from patients, ultimately imposing a 3.85% royalty on net sales. Different statutory posture—Jazz does NOT override §271(e)(4)(A)—but it shows patent remedies involving approved drugs aren’t always economically binary. 3. Hikma v. Amarin — SCOTUS 2026. Potentially the most interesting case for a PAH-only YUTREPIA. SCOTUS unanimously held that inducement requires affirmative steps encouraging infringement. Knowledge that doctors may prescribe a skinny-labeled drug for a patented use isn’t enough. That follows Warner-Lambert v. Apotex, 316 F.3d 1348: knowledge of off-label prescribing without promotion/encouragement isn’t inducement. Meaning: PAH-only label ≠ necessarily zero PH-ILD use. LQDA couldn’t promote PH-ILD. But independent physician off-label prescribing is a different issue. My prediction: Judge Andrews probably applies §271(e)(4)(A). The statute is difficult to get around because PAH + PH-ILD currently sit in one NDA. But PAH itself doesn’t infringe the ’327 patent. My base case: §271 applies → dual-indication approval goes away/becomes ineffective → FDA approves PAH-only labeling → YUTREPIA continues/returns for PAH. So the key variable isn’t whether the PAH franchise disappears. It’s the gap: days, weeks or months between the judgment and FDA approval of PAH-only labeling? Now valuation. Rather than pretend I know the exact DCF, here’s how I think about the outcomes: Hard bear: PAH + significant disruption: $35–45 Clean PAH-only: $50–60 PAH + organic physician-driven PH-ILD use: $60–80 Broader access + royalty/other remedy: $75–95 Full appellate win / PH-ILD restored: $90–120+ Those are my ranges, not Street targets. But here’s the interesting part: H.C. Wainwright removed PH-ILD entirely, assumes ~$1.1B peak PAH sales and gets $58/share. Raymond James similarly removed PH-ILD/L606 and gets ~$53. YUTREPIA is already doing real business: ~$170M Q2 revenue / ~$300M 1H26. At ~$28, the market isn’t merely pricing PH-ILD at zero. It’s pricing LQDA materially below published PAH-only valuations. That’s the setup I like. I don’t need LQDA to win everything. PAH survives intact → substantial upside. PAH + organic off-label PH-ILD → more upside. PH-ILD restored on appeal → home run. Ferring: timing matters. Norwich: what can go wrong. Jazz: remedies aren’t always binary. Hikma: skinny label doesn’t necessarily mean zero off-label use. At ~$28, I think the market is pricing something much closer to catastrophe than the range of outcomes I see. Long $LQDA
11
6
1
87
13,365
ogkoolrod retweeted
9/ And there is another piece I think the market may be underappreciating. Liquidia isn't merely a one-product patent trade. YUTREPIA was created using its PRINT particle-engineering platform, which allows Liquidia to engineer particles with precise size, shape and composition to improve deposition in the lung. There's also L606, its twice-daily extended-release inhaled treprostinil program, plus the broader potential applications of PRINT. I think there's some genuinely interesting technology optionality there.
1
1
10
1,702
ogkoolrod retweeted
Somehow I'm still green on the year on $LQDA because I took some profits in $80 s even though I added back shares in $70 s and $31 yesterday. This obviously sucks, but if liquidia can continue to sell Yutrepia seamlessly (which I think 99% likely, but therein lies the fear), I think this is oversold. I'm not rushing to add a bunch more yet though. There's a lot of psychology to cycle through the tape first. This morning was margin liquidations, which was the first part, and hopefully marks the low. But still lots of fear and uncertainty and bag holders. It won't be a quick organic bounce IMO In my opinion, ANY resolution on damages near term would be a major boost to the stock. However, I don't expect parties to come to agreement this week, so it's likely back to court we go, and timeline extended. It's trading down here on fears that the drug gets removed entirely and the uncertainty around timeline and process of other damages, but when the market agrees (either by sentiment or info) that Yutrepia continues to sell seamlessly for PAH, even if damages aren't resolved, I think the stock floats back higher somewhat. All that to say, I think we'll look back in time at these prices in the $20 s and wish we bought a good chunk for our ports and just chilled.
5
1
48
4,642
the $LQDA buying opportunity is significant. stock will double as it becomes clear that the court ruling is not existential. drug is approved for PAH. never been a drug pulled over a patent. compulsory royalty of 10% would double stock instantly. courts will not harm patients.
77
41
19
770
205,232
ogkoolrod retweeted
$LQDA Catalysts •Any day - Judge Andrews' decision on '327 patent trial vs. UTHR •2026: Yutrepia ASCENT open-label study completion •2026: Yutrepia Open-label study initiation in PH-ILD pts w/ inadequate response to Tyvaso/Tyvaso DPI •4Q26: Yutrepia Open-label study initiation in pts w/ systemic sclerosis associated Raynaud's phenomenon •1H27: Yutrepia Open-label study initiation in IPF and PPF •1H27: TRANSITION-PAH study on background Winrevair •2H27: Yutrepia pivotal RCT in PH-COPD pts
$LQDA also spoke to several prescribers this week who are actively trialing Yutrepia in their patients. Initial feedback has been positive, with use primarily being in prostacyclin naïve PH-ILD patients. Here, docs highlighted that real-world experience with Tyvaso in PH-ILD has been subpar with ~50% of patients achieving the target 64 mcg dose
6
42
9,950
ogkoolrod retweeted
$LQDA Elite "Hyper-Launch" Club 👌 as I been corrected 3 others doing what $LQDA doing $GILD $VRTX Historical Precedents: The Elite "Hyper-Launch" Club To put Liquidia’s feat into perspective, only a handful of biotechs in stock market history have ever crossed a $3.00+ EPS within their first 15–18 months of launching a drug: 1Gilead Sciences (GILD) — Sovereign of the Biotech Launch (2014) ◦The Drug: Sovaldi / Harvoni (Hepatitis C cure). ◦The Result: Gilead didn't just hit $3.00 in EPS—they blew past it. Within 12 months of launching Sovaldi, Gilead's annual EPS skyrocketed from roughly $1.81 toover $8.00 because the drug cured a massive, desperate patient population instantly. 2Moderna (MRNA) & BioNTech (BNTX) — The Pandemic Anomalies (2021) ◦The Drug: Comirnaty & Spikevax (COVID-19 mRNA vaccines). ◦The Result: Driven by unprecedented global government purchase mandates, both companies transitioned from clinical-stage losses to booking$20.00 to $39.00+ in EPS within 12 to 15 months of commercial distribution. 3Vertex Pharmaceuticals (VRTX) — The Monopolist Expansion (2012 / 2019) ◦The Drug: Kalydeco (2012) and later Trikafta (2019) for Cystic Fibrosis.
$LQDA not sure I know of another #Biotech that after 15 months launching would do $3 bucks EPS ?? - anyone remember one ??
6
5
2
39
21,406
ogkoolrod retweeted
$LQDA $90-100+ incoming next few weeks as Judge Andrews is about to remove this overhang
"In light of concerns about the possibility of waiving work product privilege... the Opposition to the Motion to Strike did not address the details of the version control error." So that surely means they had discovered the "error" but elected not to disclose it. Speaks loudly to "unclean hands" which would be dispositive of the whole suit, not just the common-ownership claims. $LQDA $UTHR
1
2
1
54
10,540
The S&P put/call skew just collapsed to 0.71. Not a low. The lowest reading on record. The 10-year average is 12. The 2020 panic peaked at 34. We're at 0.71. What this measures: how much investors pay to protect against a crash versus betting on a rally. At 0.71, crash protection is essentially free. Nobody wants it. Think about what that means. After two years of gains, at record concentration, with households at record equity exposure, the options market has priced hedging like insurance on a house that cannot burn. History's lesson is consistent: markets don't crash when everyone fears a crash. Fear is the hedge. This chart says the hedge is gone. Nobody buys insurance at the top. That's what makes it the top?
63
219
49
1,114
326,864
What a rotten deal we made with Iran. We get nothing (except laughter at our stupidity). They get everything, including delay and big cash!
1,369
12,860
2,373
33,628
🤡🌎 Every single word of this fairy tale is a lie, including every "if", "and", and "but".
🚨 BREAKING: THE IRAN DEAL IS DONE — AND ALL THE URANIUM GETS DESTROYED 🚨 Buried a SKYSCRAPER deep… and the U.S. is the ONLY country that can dig it out 👀 NO enrichment. NO sunset clause. NO money up front — they PERFORM, then get PAID 💰 Gulf allies just pledged $300 BILLION to rebuild the wreckage 💥 80% of Iran's military DECIMATED — this could be Trump's CROWNING ACHIEVEMENT 🇺🇸
20
103
2
594
22,243
"Iran reaffirms that under no circumstances will Iran ever seek, develop or acquire any nuclear weapons." Oh wait, that was literally the JCPOA.
26
54
6
615
38,445
There is no way to spin this, Trump has lost a tremendous war to the Iranians who have outsmarted him and are in a much stronger position than before Feb 27th. No matter what happens Iran will be getting billions of dollars from the US government to end this absolute disaster of US Foreign Policy. Of course Trump will spin this as a massive win for the USA and tell his loyal followers that because of his "expert" negotiations, Iran has agreed to not develop a nuclear bomb, but this has been the consistent message from Iran for years, and in fact this was already guaranteed under Obama's deal.
BREAKING: Iran says the US has agreed to pay $300 billion in reconstruction funds directly to Iran as part of the deal Pakistan announced, alongside the release of $24 billion in frozen funds with $12 billion released before negotiations even start, per Mehr News. This directly contradicts Trump's & Vance's claim that no funds will be transferred to Iran at all. If Trump denies this is true, there never was a deal. If Trump confirms, the US has fully capitulated to Iran's demands.
302
603
27
2,765
173,066
🚨 BREAKING: Trump's new peace deal with Iran includes a $340 billion payment by the United States to Iran.
226
214
217
796
2,073,704
ogkoolrod retweeted
JUST IN: 🇺🇸🇮🇷 US to release $12,000,000,000 in frozen assets to Iran.
455
2,572
292
19,245
1,265,332
🇺🇸 Historic Flag Day 2026 🇺🇸 🔴 Trump turns 80 years old ⚪️ Gladiator fights at the White House 🔵 The most decisive strategic defeat in American history is announced with full capitulation to Iranian terms This will stick in their craw. There is more war yet to come.
🚨 IT’S FIGHT NIGHT AT THE WHITE HOUSE! TUNE IN NOW! @ufc 🇺🇸🇺🇸🇺🇸
20
122
3
522
26,607
$300 Billion! 0 Sanctions! Tell me….who is winning?
Mehr News has released a short version of the 14-clauses of the MoU that will be signed on Friday, between Iran & US. 1. The permanent and immediate halt of war on all fronts, including Lebanon. 2. A U.S. commitment not to interfere in Iran’s internal affairs and to respect the sovereignty of the Islamic Republic of Iran. 3. The complete lifting of the naval blockade within 30 days. 4. A U.S. commitment to withdraw its forces from the areas surrounding Iran. 5. The reopening of the Strait of Hormuz within 30 days under Iranian “arrangements”. 6. The suspension of oil sanctions, petrochemical products and derivatives, and Iran’s full access to the financial proceeds from them. 7. The requirement for the US & its allies to present reconstruction plans for Iran worth at least $300 billion. 8. Sixty days of negotiations to reach a final agreement based on nuclear issues and the complete lifting of primary and secondary U.S. sanctions, as well as UN Security Council resolutions and resolutions of the IAEA Board of Governors. 9. Iran’s reiteration of its commitment under the NPT not to produce nuclear weapons. 10. During the negotiation period, the U.S. has committed not to add to its forces in the region and not to impose any new sanctions. 11. The release of $24 billion of Iran’s frozen funds during the 60-day period of final negotiations. Half of this amount must be made available to Iran before the negotiations begin. 12. The formation of a supervisory mechanism to implement the agreement. 13. The final agreement will be approved through a UN Security Council resolution. 14. Final negotiations will not begin before half of Iran’s frozen funds are released, Iran’s oil sanctions are suspended, and the naval blockade is lifted. The final agreement will be limited only to the fate of enriched materials and enrichment, sanctions relief, and the program for rebuilding Iran’s economy. Discussions about Iran’s missile program and support for Resistance groups have been definitively removed from the agenda.
4
2
7
1,638
The predicament Trump is in, and has been since he started the Iran War with Netanyahu, illustrates why it was so stupid and destructive to start this war in the first place. From the start, there were only two real options: 1) Take seriously all the stated war aims and try to fulfill them, which would require a protracted, self-destructive, devastating, years-long war of the kind Trump spent a decade vowing to avoid, or, 2) End the war quickly and prematurely, and then have to scurry around to find some way to claim that the US "won", which would -- at a minimum -- force Trump to credibly claim he got more than Obama's JCPOA gave, thus justifying all the massive bloodshed, instability and cost from the war. If reports are correct (and it's a big "if"), Trump is choosing option (2). But his case that he actually won anything consequential beyond what the Obama Deal provided is close to laughable, while the losses to the US (and wins for Iran) are self-evident.
199
383
11
2,611
144,054
ogkoolrod retweeted
$SPCX IPO has bent tons of rules to IPO faster and let more retail in. And y’all out here thinking they doing you favors. Stay blessed.
17
9
2
238
23,431